These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 38735258)
1. Clinical evidence for the prognostic impact of metformin in cancer patients treated with immune checkpoint inhibitors. Shen J; Ye X; Hou H; Wang Y Int Immunopharmacol; 2024 Jun; 134():112243. PubMed ID: 38735258 [TBL] [Abstract][Full Text] [Related]
2. Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Shen J; Hou H; Liang B; Guo X; Chen L; Yang Y; Wang Y Front Immunol; 2023; 14():1155104. PubMed ID: 37153578 [TBL] [Abstract][Full Text] [Related]
3. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Chen H; Han KD; He ZJ; Huang YS Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149 [TBL] [Abstract][Full Text] [Related]
4. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts. Wu Q; Liu J; Wu S; Xie X Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728 [TBL] [Abstract][Full Text] [Related]
5. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C Front Immunol; 2023; 14():1070076. PubMed ID: 36776847 [TBL] [Abstract][Full Text] [Related]
6. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595 [TBL] [Abstract][Full Text] [Related]
7. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis. Tan Q; Liu S; Liang C; Han X; Shi Y Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899 [TBL] [Abstract][Full Text] [Related]
8. Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors. Kuang T; Qiu Z; Wang K; Zhang L; Dong K; Wang W Front Immunol; 2024; 15():1326083. PubMed ID: 38410508 [TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Chen X; Meng F; Jiang R Front Oncol; 2021; 11():746976. PubMed ID: 34900692 [TBL] [Abstract][Full Text] [Related]
10. Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors. Yan X; Liu P; Li D; Hu R; Tao M; Zhu S; Wu W; Yang M; Qu X Int Immunopharmacol; 2022 Dec; 113(Pt A):109383. PubMed ID: 36330916 [TBL] [Abstract][Full Text] [Related]
11. Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study. Chiang CH; Chen YJ; Chiang CH; Chen CY; Chang YC; Wang SS; See XY; Horng CS; Peng CY; Hsia YP; Peng CM; Chiang CH Cancer Immunol Immunother; 2023 Jun; 72(6):1951-1956. PubMed ID: 36651967 [TBL] [Abstract][Full Text] [Related]
12. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis. Tian BW; Han CL; Wang HC; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Yang LS; Tan SY; Dong ZR; Yan YC; Wang DX; Li T Clin Exp Metastasis; 2023 Aug; 40(4):255-287. PubMed ID: 37308706 [TBL] [Abstract][Full Text] [Related]
13. Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Yu J; Meng F; Sui W; Yu J; Shen J Front Pharmacol; 2024; 15():1378577. PubMed ID: 38895628 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy. Kuang T; Zhang L; Qiu Z; Zhang Y; Wang W Front Immunol; 2023; 14():1261202. PubMed ID: 38077332 [TBL] [Abstract][Full Text] [Related]
15. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Zhang N; Jiang J; Tang S; Sun G Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. Wang R; Lin N; Mao B; Wu Q J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207 [TBL] [Abstract][Full Text] [Related]
17. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis. Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X Front Oncol; 2022; 12():976224. PubMed ID: 36185176 [TBL] [Abstract][Full Text] [Related]
18. Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents. Wang Y; Hu Y; Wang T; Che G; Li L Front Pharmacol; 2023; 14():1123834. PubMed ID: 36969876 [No Abstract] [Full Text] [Related]
19. Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis. Li L; Guo Y; Gong B; Wang S; Wang MM; Sun P; Jiang S; Yang L Front Immunol; 2024; 15():1385802. PubMed ID: 38994363 [TBL] [Abstract][Full Text] [Related]
20. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors. Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H Front Immunol; 2022; 13():968729. PubMed ID: 35967438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]